抗体药物偶联物-话题@MedSci

#抗体药物偶联物#

23篇内容 | 1944人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1413825, encodeId=cbf6141382533, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, objectTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, objectType=article, longId=190853, objectId=1643190853f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1643190853f0, replyNumber=0, likeNumber=112, createdTime=2020-03-27, rootId=0, userName=chendoc243, userId=f5ea3025344, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1643190853f0, moduleTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1643190853f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413824, encodeId=f9e1141382475, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, objectTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, objectType=article, longId=186821, objectId=44e318682186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e318682186, replyNumber=0, likeNumber=68, createdTime=2020-01-29, rootId=0, userName=chendoc243, userId=f5ea3025344, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e318682186, moduleTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44e318682186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413823, encodeId=db20141382377, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, objectTitle=抗体药物偶联物OBI-999治疗胰腺癌获得FDA孤儿药物认定, objectType=article, longId=185335, objectId=6cc718533567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc718533567, replyNumber=0, likeNumber=65, createdTime=2019-12-29, rootId=0, userName=chendoc243, userId=f5ea3025344, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc718533567, moduleTitle=抗体药物偶联物OBI-999治疗胰腺癌获得FDA孤儿药物认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc718533567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413822, encodeId=52f7141382291, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, objectTitle=抗体药物偶联物治疗肺癌：U3-1402和DS-1062的临床结果更新将在2019年世界肺癌大会上发表, objectType=article, longId=178109, objectId=29b21e810910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29b21e810910, replyNumber=0, likeNumber=77, createdTime=2019-08-24, rootId=0, userName=chendoc243, userId=f5ea3025344, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29b21e810910, moduleTitle=抗体药物偶联物治疗肺癌：U3-1402和DS-1062的临床结果更新将在2019年世界肺癌大会上发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29b21e810910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413821, encodeId=d9081413821a4, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, objectTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, objectType=article, longId=165882, objectId=9c0116588208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0116588208, replyNumber=0, likeNumber=62, createdTime=2019-05-13, rootId=0, userName=chendoc243, userId=f5ea3025344, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0116588208, moduleTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0116588208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413820, encodeId=4e4e141382056, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, objectTitle=Oncotarget：新型抗体药物偶联物ENDOS/ADC有持续抗骨肉瘤作用！, objectType=article, longId=108426, objectId=8e04108426aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e04108426aa, replyNumber=0, likeNumber=79, createdTime=2017-08-12, rootId=0, userName=chendoc243, userId=f5ea3025344, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e04108426aa, moduleTitle=Oncotarget：新型抗体药物偶联物ENDOS/ADC有持续抗骨肉瘤作用！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e04108426aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413819, encodeId=38b3141381978, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, objectTitle=Nat Protoc：上海药物所发展定点抗体药物偶联物新策略及抗体糖工程技术方案, objectType=article, longId=108336, objectId=345a108336ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=345a108336ae, replyNumber=0, likeNumber=67, createdTime=2017-08-11, rootId=0, userName=chendoc243, userId=f5ea3025344, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=345a108336ae, moduleTitle=Nat Protoc：上海药物所发展定点抗体药物偶联物新策略及抗体糖工程技术方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=345a108336ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413818, encodeId=a967141381868, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, objectTitle=CLIN CANCER RES ：Anti-NaPi2b抗体药物偶联物作为非小细胞肺癌和卵巢癌治疗的临床前景, objectType=article, longId=53129, objectId=8b7d53129cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b7d53129cc, replyNumber=0, likeNumber=77, createdTime=2015-07-11, rootId=0, userName=chendoc243, userId=f5ea3025344, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b7d53129cc, moduleTitle=CLIN CANCER RES ：Anti-NaPi2b抗体药物偶联物作为非小细胞肺癌和卵巢癌治疗的临床前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b7d53129cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗体药物偶联物

2020-05-29

chendoc243 (审核中...)

前往app查看评论内容

#抗体药物偶联物#

抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌

2020-03-27

chendoc243 (审核中...)

前往app查看评论内容

#抗体药物偶联物#

抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点

2020-01-29

chendoc243 (审核中...)

前往app查看评论内容

#抗体药物偶联物#

抗体药物偶联物OBI-999治疗胰腺癌获得FDA孤儿药物认定

2019-12-29

chendoc243 (审核中...)

前往app查看评论内容

#抗体药物偶联物#

抗体药物偶联物治疗肺癌：U3-1402和DS-1062的临床结果更新将在2019年世界肺癌大会上发表

2019-08-24

chendoc243 (审核中...)

前往app查看评论内容

#抗体药物偶联物#

阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景

2019-05-13

chendoc243 (审核中...)

前往app查看评论内容

#抗体药物偶联物#

Oncotarget：新型抗体药物偶联物ENDOS/ADC有持续抗骨肉瘤作用！

2017-08-12

chendoc243 (审核中...)

前往app查看评论内容

#抗体药物偶联物#

Nat Protoc：上海药物所发展定点抗体药物偶联物新策略及抗体糖工程技术方案

2017-08-11

chendoc243 (审核中...)

前往app查看评论内容

#抗体药物偶联物#

CLIN CANCER RES ：Anti-NaPi2b抗体药物偶联物作为非小细胞肺癌和卵巢癌治疗的临床前景

2015-07-11

科室
- - 订阅+
  - 更多科室
工具
服务